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Background: The majority of bicarbonate based dialysis fluids are acidified with acetate. Citrate, a well known
anticoagulant and antioxidant, has been suggested as a biocompatible alternative. The objective of this study was
to evaluate short term safety and biocompatibility of a citrate containing acetate-free dialysis fluid.
Methods: Twenty four (24) patients on maintenance dialysis three times per week, 13 on on-line hemodiafiltration
(HDF) and 11 on hemodialysis (HD), were randomly assigned to start with either citrate dialysis fluid (1 mM citrate,
1.5 mM calcium) or control fluid (3 mM acetate, 1.5 mM calcium) in an open-labeled cross-over trial (6 + 6 weeks
with 8 treatments wash-out in between). Twenty (20) patients, 11 on HDF and 9 on HD were included in the
analyses. Main objective was short term safety assessed by acid–base status, plasma ionized calcium and
parathyroid hormone (PTH). In addition, biocompatibility was assessed by markers of inflammation (pentraxin 3
(PTX-3), CRP, IL-6, TNF-α and IL-1β) and thrombogenicity (activated partial thromboplastin time (APTT) and visual
clotting scores).
Results: No differences dependent on randomization order or treatment mode (HD vs. HDF) were detected. Citrate
in the dialysis fluid reduced the intra-dialytic shift in pH (+0.04 week 6 vs. +0.06 week 0, p = 0.046) and base excess
(+3.9 mM week 6 vs. +5.6 mM week 0, p = 0.006) over the study period. Using the same calcium concentration
(1.5 mM), citrate dialysis fluid resulted in lower post-dialysis plasma ionized calcium level (1.10 mM vs. 1.27 mM for
control, p < 0.0001) and higher post-dialysis PTH level (28.8 pM vs. 14.7 pM for control, p < 0.0001) while pre-dialysis
levels were unaffected. Citrate reduced intra-dialytic induction of PTX-3 (+1.1 ng/ml vs. +1.4 ng/ml for control,
p = 0.04) but had no effect on other markers of inflammation or oxidative stress. Citrate reduced visual clotting in
the arterial air chamber during HDF (1.0 vs. 1.8 for control, p = 0.03) and caused an intra-dialytic increase in APTT
(+6.8 s, p = 0.003) without affecting post-dialysis values compared to control.
Conclusions: During this small short term study citrate dialysis fluid was apparently safe to use in HD and on-line
HDF treatments. Indications of reduced treatment-induced inflammation and thrombogenicity suggest citrate as a
biocompatible alternative to acetate in dialysis fluid. However, the results need to be confirmed in long term
studies.
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Reintroduction of bicarbonate as the main buffer in dialy-
sis fluids in the late 1980’s revolutionized hemodialysis,
but since then no major improvements in dialysis fluid
composition have been made. Preparation of bicarbonate
based dialysis fluids requires an acidic component in
order to balance pH and most commonly acetic acid is
used in a concentration of 3–10 mM. This is up to a
hundred times higher than normal plasma acetate levels
and typically results in a substantial increase in plasma
acetate which may promote hemodynamic instability,
inflammation, and acidosis [1-3]. Citric acid has been
proposed as a more biocompatible acidifier being a nat-
ural metabolite and antioxidant with anti-inflammatory
properties.
Metabolic acidosis of chronic kidney disease is associ-
ated with protein wasting and malnutrition and can cause
cardiovascular instability due to impaired myocardial con-
tractility [4,5]. Unlike acetate, citrate is rapidly metabolized
into carbon dioxide and energy. Clinical studies have
shown that citrate containing dialysis fluids can improve
both the acidotic and nutritional state in patients com-
pared to acetate containing fluids [6-8].
Cardiovascular disease (CVD) is the most common
cause of death among dialysis patients with a 10–20-
fold higher mortality rate than in the general population
[9-11]. Inflammation and oxidative stress have been
identified as specific risk factors for developing CVD in
dialysis patients and are proposed as potential therapy
targets [10,12-14]. By complex binding calcium citrate
inhibits both coagulation and complement activation
and may reduce the treatment-induced inflammatory
response [15,16]. Citrate also reduces oxidative stress by
chelating multivalent cations like iron and copper and
has been shown to restore mitochondrial glutathione
levels and decrease markers of cellular injury and free
radical formation [17-19]. Apart from causing inflam-
mation blood activation may also reduce dialysis effi-
ciency by inducing clogging of the dialyzer. Clinical
studies have shown improved clearance when using a
citrate containing dialysis fluid compared to a regular
dialysis fluid [20,21].
The aim of this randomized controlled cross-over pilot











Figure 1 Study design flow diagram.of a citrate containing acetate free dialysis fluid during
hemodialysis (HD) and post-dilution hemodiafiltration
(HDF). Safety was assessed by patient acid base status and
calcium balance (plasma ionized calcium and PTH levels).
Fluid biocompatibility was assessed by various markers of
inflammation, oxidative stress and coagulation activation.
In addition, potential citrate accumulation, hemodynamics
and treatment efficiency were investigated.
Methods
Patients and study design
The study was conducted in accordance with the Inter-
national Standard ISO 14155, and ethical principles,
derived from the Declaration of Helsinki and approved by
the regional ethical review board of Lund University. All
patients were legally adults and signed an informed con-
sent to participate in the study prior to any study related
procedures. The study was a randomized controlled cross-
over study with a wash-out period, Figure 1. Twenty-four
stable patients (16 male and 8 female) undergoing main-
tenance hemodialysis three times per week at the Skåne
University Hospital in Lund and Malmö, Sweden, were
recruited and enrolled. Patients were stratified according
to dialysis centre (16 in Lund and 8 in Malmö) and treat-
ment mode (13 on HDF and 11 on HD). Patients were
randomized to treatment thrice weekly for six weeks with
either the citrate containing dialysis fluid or the control
acetate containing dialysis fluid. After a wash-out period
(eight consecutive treatments with control fluid) patients
switched fluid for another six weeks. The start and end of
each study period and all data collection and blood sam-
pling occurred on mid week treatments. Randomization
was performed using block randomization with site (Lund
or Malmö) and treatment mode (HD or HDF) as strati-
fication variables. Randomized allocation occurred after
enrollment and was conducted by an independent CRO.
First patient in occurred 13th of January 2011 and last
patient out 19th of May 2011.
The study was performed using the Gambro dialysis
monitor (AK 200™ ULTRA S) and Gambro single-use high
flux dialyzers (Polyflux™ 170H or Polyflux™ 210H). Both
the citrate containing A-concentrate (SelectBag® Citrate)
and the control (SelectBag® One) were used together
with sodium bicarbonate (BiCart®) and sodium chloride 6 weeks on 
sis fluid, n=12
 6 weeks on
is fluid, n=12
Switched to 6 weeks on
citrate dialysis fluid, n=12
Switched to 6 weeks on
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compositions see Table 1. Dialysis fluid flow rate was
kept constant at 500 ml/min.
Anticoagulation was performed using low molecular
weight heparin (N= 23; single bolus dose) or unfractionated
heparin (N = 1; initial bolus + second bolus). Anticoagulation
prescriptions and concomitant medications were unchanged
during the study period. Blood pressure, heart rate, blood
flow rate, ultrafiltration rate and extracorporeal arterial
and venous pressures were recorded. Treatment efficiency
was measured as ionic Kt/V (Diascan® monitoring tool).
Clotting degree in dialyzers, venous drip chambers and
arterial expansion chambers were rated by qualified nurses
according to validated scales. For venous and arterial
chambers no clotting was rated as 0 and complete clotting
as 4. For dialyzers no clotting was scored as 0 and
complete clotting as 3.
Laboratory analyses
Arterial blood samples were taken pre- and post-dialysis
at the mid-week dialysis sessions. Safety parameters (ion-
ized calcium, PTH, citrate, hemodynamics and acid base
parameters) were measured every second week and
markers of coagulation, inflammation and oxidative stress
were measured at the beginning and end of each study
period. Plasma was separated and kept frozen at −80°C if
not analyzed immediately.
The following routine samples were analyzed at the
Department of Clinical Chemistry Skåne University Hos-
pital: blood erythrocyte, leukocyte and thrombocyte counts,
hemoglobin, hematocrit, sodium, potassium, chloride, total
and ionized calcium, parathyroid hormone (PTH), urea,
albumin, pH, carbon dioxide pressure (pCO2) and base
excess. Inflammatory markers C-reactive protein (CRP),
interleukin 6 (IL-6), interleukin 1β and tumor necrosis
factor α were analyzed on site by standard methods. Ac-
tivated partial thromboplastin time (APTT) was assayed
optically with equipment routinely applied at the study
sites.
Citrate plasma levels were analyzed in heparinized
plasma with a validated chromatographic (HPLC) methodTable 1 Dialysis fluid compositions
Compound Citrate fluid Control fluid
Potassium (mM) 2 or 3 2 or 3
Magnesium (mM) 0.5 0.5
Calcium (mM) 1.5 1.5
Sodium (mM) Variable Variable
Bicarbonate (mM) 34-36 34-36
Glucose (mM) 5.5 5.5
Citrate (mM) 1 0
Acetate (mM) 0 3developed by Gambro Research, Lund. Total advanced
glycation end-products were determined spectrophoto-
metrically and carboxymethyl-lysine and pentosidine by
commercial ELISA kits (Cell Biolabs, Inc. USA) at
Gambro Research, Lund.
Several biocompatibility parameters were analyzed at
the Department of Laboratory Medicine at Karolinska
University Hospital in EDTA-treated plasma. Pentraxin
3 (PTX-3) was analyzed by a commercially available ELISA
kit (Perseus Preteomics Inc., Japan). Total aminothiols were
analyzed by a validated HPLC method, modified advanced
oxidation protein products by a colometric bioassay and 8-
oxo-2′-deoxyguanosine by a competitive ELISA kit (Japan
Institute for Control of Aging, Shizuoka, Japan).
Statistics
Analyses were done using standard analysis of covari-
ance for a two-period cross over study. Within patient
difference between the two periods, divided by treat-
ment mode (HD/HDF) and study site, were analyzed
using the Wilcoxon Signed Rank Sum test. Period and
carry-over effects were non-significant so the within
patient difference between the two periods were used
for analyses. Data in tables and graphs are presented as
means ± standard error of mean (SEM) unless other-
wise stated. All statistical tests are interpreted at the
5% significance level (2-tailed). Sub-analyzes power cal-
culations were done using nQuery Advisor® 7.0 based on
two group t-test (paired) of equal means.
Results
Study population characteristics and statistics
Twenty-four patients on maintenance hemodialysis three
times per week were included and entered the study, 13
treated with HDF and 11 with HD. One patient died dur-
ing a planned angiography and three more were excluded
from per protocol analysis due to protocol deviations.
Data from a total of 20 patients (11 on HDF and 9 on HD)
were included in the per protocol analysis and presented
in this paper. No differences between treatment modes
(HD/HDF) were detected and all data presented include
both treatment modes. No carry over effects were detected
and data from both study arms are combined. Patient
characteristics are presented in Table 2 and adverse events
in Additional file 1: Table S1.
Acid-base status
Citrate dialysis fluid significantly reduced the intra-
dialytic pH shift in arterial blood over the six week study
period (+0.04 ±0.01 at week 6 vs. +0.06 ±0.01 at week 0,
p = 0.046), associated with a trend towards increased
pre-dialysis pH, Figure 2A. Citrate dialysis fluid also
induced a small but significant increase in post-dialysis
Table 2 Study population characteristics at inclusion
Lund clinic Malmö clinic Total
Parameter, Mean ± StDev HD HDF HD HDF Mean (range)
Gender (female : male) 2 : 5 3 : 6 2 : 2 1 : 3 8 : 16
Age (years) 74.3 ±11.1 73.9 ±7.6 61.7 ±20.6 59.8 ±15.7 70 (40-92)
Dry weight (kg) 71.9 ±10.6 80.0 ±13.2 77.4 ±25.5 80.4 ±12.2 77 (53-103)
Time on dialysis (years) 2.0 ±2.7 3.2 ±2.1 1.4 ±1.2 8.3 ±11.9 3.4 (0.2-26)
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ever, no trend towards an increase over time was seen.
During the citrate dialysis fluid period the intra-dialytic
base excess shift was significantly reduced (+3.9 ±0.5 mM
at week 6 vs. +5.6 ±0.5 mM at week 0, p = 0.006) and after
6 weeks it was significantly lower compared to control
(+3.9 ±0.5 vs. +5.0 ±0.5 mM, p = 0.02), Figure 2B. The
effect was associated with a significant increase in pre-
dialysis base excess during the citrate study period
(2.4 ±0.5 mM at week 6 vs. 1.0 ±0.4 mM at week 0,
p = 0.03). Citrate dialysis fluid resulted in a small but sig-
nificant increase in post-dialysis base excess (6.4 ±0.4 vs.
6.0 ±0.5 mM for control, p = 0.04) but no trend towards
an increase over time was detected.
Intra-dialytic shift in carbon dioxide pressure (pCO2)
was significantly lower when using citrate dialysis fluid
compared to control (+0.16 ±0.09 vs. +0.39 ±0.14 kPa,
p = 0.02), Figure 2C. The effect was associated with a
significant increase in pre-dialytic pCO2 (5.48 ±0.15 vs.
5.34 ±0.15 kPa for control, p = 0.04) while post-dialysis
pCO2 were similar between products (5.64 ±0.14 vs.
5.72 ±0.17 kPa for control, ns), Figure 2C. Acid-base
parameters were measured pre- and post-dialysis every
second week (week 0, 2, 4 and 6) during each study
period. Power analyses of reduced intra-dialytic change
in pH and base excess at the end of the citrate period
gives a power of approximately 30 and 50% respectively.
Calcium balance and regulation
With 1.5 mM calcium in the dialysis fluid the presence
of 1 mM citrate induced a small but significant intra-
dialytic reduction in ionized calcium (1.14 ±0.02 mM
pre-dialysis vs. 1.10 ±0.01 mM post-dialysis, p < 0.0001)
while there was a significant increase in post-dialysis
calcium with the control fluid (1.14 ±0.02 mM pre-
dialysis vs. 1.27 ±0.01 mM post-dialysis, p < 0.0001),
Figure 3A. Pre-dialysis levels of ionized calcium did not
differ between products, or over time, and total calcium
levels were constant. Ionized calcium was measured
pre- and post-dialysis every second week (week 0, 2, 4
and 6) during each study period while total calcium was
analyzed pre-dialysis at the beginning and end (week 0
and week 6) of each period.
With citrate dialysis fluid there was no significant
intra-dialytic shift in PTH levels (26.7 ±3.4 pM pre-dialysis vs. 28.8 ±4.1 pM post-dialysis, ns) while the con-
trol fluid induced a significant decrease in post-dialysis
PTH levels (24.3 ±4.3 pM pre-dialysis vs. 14.7 ±3.3 pM
post-dialysis, p < 0.001), Figure 3B. Pre-dialysis levels of
PTH did not differ between products. PTH levels were
measured pre- and post-dialysis every second week
(week 0, 2, 4 and 6) during each study period.
Citrate tolerance
Citrate plasma levels increased significantly during dia-
lysis with citrate containing dialysis fluid (0.04 ±0.01
pre-dialysis vs. 0.28 ±0.03 mM post-dialysis, p < 0.0001).
Citrate levels returned to baseline between treatments
and no trend towards accumulation could be detected,
Figure 4. Citrate plasma levels were not affected during
the control period (data not shown). Citrate levels were
measured pre- and post-dialysis every second week
(week 0, 2, 4 and 6) during each study period.
The need for medical staff intervention did not differ
between periods and no product related adverse event or
significant side effects were reported (Additional file 1:
Table S1). Blood count parameters; leucocytes, erythro-
cytes, thrombocytes, hemoglobin and hematocrit, were
all within normal variations and did not differ between
products.
Inflammation
Citrate dialysis fluid induced a significantly lower intra-
dialytic rise in PTX-3 compared to control (+1.1 ±0.3
vs. +1.4 ±0.3 ng/ml, p = 0.04), suggesting less treatment-
induced inflammation, Figure 5. Pre-dialysis values of
PTX-3 were not significantly different between products
(1.9 ±0.4 vs. +1.8 ±0.3 ng/ml for control, ns). Citrate’s
ability to reduce the intra-dialytic increase in PTX-3
compared to control rendered 99% power.
No differences were detected between the two study
products regarding plasma levels of other markers of in-
flammation, including oxidative stress markers and AGEs,
Additional file 1: Table S2. All inflammatory markers were
measured at beginning and end (week 0 and week 6) of
each study period.
Thrombogenicity
Citrate dialysis fluid induced a significant intra-dialytic
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Figure 3 Analyses of calcium balance over the study period.
A) Intra-dialytic change in plasma ionized calcium levels at each
sampling occasion when using citrate dialysis fluid compared to
control. B) Intra-dialytic change in plasma PTH levels at each
sampling occasion when using citrate dialysis fluid compared to
control. Black bars represent pre-dialysis values and white bars
post-dialysis values. Bars show means and error bars represent
SEM, n = 20. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 and
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Figure 2 Impact of citrate dialysis fluid on acid–base status.
A) Intra-dialytic change in pH at study start (Week 0) and study end
(Week 6). B) Intra-dialytic change in Base Excess at study start
(Week 0) and study end (Week 6). C) Overall intra-dialytic change in
carbon dioxide pressure when using citrate dialysis fluid compared
to control. Black bars represent pre-dialysis values and white bars
post-dialysis values. Bars show means and error bars represent SEM,
n = 20. * = p < 0.05 and ** = p < 0.01.
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(38.1 ±2.4 s pre-dialysis vs. 40.6 ±2.3 s post-dialysis, ns).
Apart from the intra-dialytic increase there were no
significant differences in APTT between periods. APTT
was measured at beginning and end of each studyperiod. Citrate’s small but significant effect on APTT
compared to control rendered 99% power.
The arterial expansion chamber during HDF showed
significantly lower clotting score after dialysis with
citrate dialysis fluid compared to control (0.9 ±0.2 vs.
1.6 ±0.3, p = 0.03). Inspection of the venous drip chamber
did not show any significant differences between citrate
dialysis fluid and control (1.5 ±0.3 vs. 1.8 ±0.3, ns)
and neither did inspection of the dialyzer (0.6 ±0.2
vs. 0.6 ±0.2, ns).
Hemodynamics and treatment efficiency
Pre-dialysis mean arterial pressure (MAP) was similar
between products. Dialysis treatment with citrate dialysis













Figure 4 Effect on plasma citrate levels over the citrate dialysis
fluid study period. Black bars represent pre-dialysis values and
white bars post-dialysis values. Bars show means and error bars


























Figure 6 Changes in mean arterial blood pressure during the
dialysis treatment. Diamonds represent citrate dialysis fluid and
squares control dialysis fluid. Symbols show means and error bars
represent SEM, n = 20, * = p < 0.05.
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p = 0.03). Relative to pre-dialysis value MAP tended to
be lower throughout the treatment when using citrate
dialysis fluid compared to control fluid, Figure 6. There
were no differences in heart rate between study prod-
ucts and no product related hypotension episodes were
reported (data not shown). Hemodynamic parameters
were recorded every second week (week 0, 2, 4 and 6)
during each study period.
Mid-dialysis ionic Kt/V was significantly higher using
citrate dialysis fluid compared to control (0.76 ±0.04 vs.
0.69 ±0.03 for control, p = 0.007) but there was no signifi-
















Figure 5 Effect of citrate dialysis fluid on inflammation
presented as overall intra-dialytic change in PTX-3 expression
when using citrate dialysis fluid compared to control. Black bars
represent pre-dialysis values and white bars post-dialysis values. Bars
show means and error bars represent SEM, n = 20. * = p < 0.05.for control, ns), Table 3. No differences in plasma levels
of sodium, potassium, chloride, urea and albumin were
detected (data not shown). Dialysis efficiency was ana-
lyzed at the beginning and end (week 0 and week 6) of
each study period.
Discussion
Apart from the introduction of ultrapure fluids no major
steps towards more physiological dialysis fluids have
been implemented since the introduction of bicarbonate
based dialysis in the 1980’s [22,23]. In addition, the pos-
sibility to improve tolerance to treatment by adding bio-
logically active substances to the dialysis fluid has only
recently been addressed. In this small sized randomized
controlled pilot study we addressed potential benefits, as
well as short term safety, of an acetate-free dialysis fluid
containing 1 mM of citrate.
The most notable finding in this study was the change
in patient acid-base status, reflected by both reduced
intra-dialytic shifts and increased pre-dialysis steady
state levels of pH as well as base excess. Citrate dialysis
fluid rendered higher pre-dialysis levels of base excess,
carbon dioxide pressure and pH, a combination that
indicates reduced metabolic acidosis [24]. Clinical effects
of citrate dialysis fluids on acid–base status have been
reported before. A short term cross-over study with al-
ternating weeks of citrate (0.8 mM) and regular dialysis
fluid showed increased pre-dialysis bicarbonate levels
but unexpectedly lower post-dialysis bicarbonate and pH
with citrate [25]. However, the study was not designed
to detect changes over time. Another study reported
improved pre-dialysis steady state bicarbonate and pH
after three months with citrate dialysis fluid (0.67 mM)
compared to an acetate dialysis fluid [8]. In this study
Table 3 Study treatment characteristics described as mean post-dialysis values, (n = 20)
Parameter, Mean ± StDev Citrate fluid Control fluid p-value
Treatment time (h) 4-5 4-5 ns
QB (ml/min) 324 ±35 321 ±35 ns
UF rate (ml/h) 438 ±288 513 ±306 ns
Substitution volume if HDF (l), n = 11 28.2 ±5.1 27.7 ±6.6 ns
Diascan Kt/V 1.49 ±0.26 1.47 ±0.29 ns
Systolic BP (mmHg) 146 ±25 146 ±26 ns
Diastolic BP (mmHg) 76 ±12 74 ±12 ns
Pulse (bpm) 78 ±15 76 ±12 ns
Grundström et al. BMC Nephrology 2013, 14:216 Page 7 of 9
http://www.biomedcentral.com/1471-2369/14/216however, the control fluid contained 8 mM acetate and
bicarbonate settings differed between citrate and control
fluid (35 mM vs. 25 mM) making it hard to evaluate the
effect of citrate. A more efficient management of patient
acid–base status, where intra- and inter-dialytic fluctu-
ations are avoided, could reduce treatment-induced
discomfort and improve patient well-being [4]. Today
acidosis is routinely managed by loading the patients
with non-physiological levels of bicarbonate during
dialysis. Citrate in the dialysis fluid may help reducing
acidosis and for patients who do not suffer from acidosis,
like our study population, citrate may provide an oppor-
tunity to make dialysis more physiological by reducing the
bicarbonate load. During our study each patient received
the same prescription of bicarbonate throughout the study
(34-36 mM).
Our short term study was not optimized for measuring
long term effects of citrate dialysis fluid on inflammation
but we observed signs of reduced treatment-induced in-
flammation. The intra-dialytic rise in PTX-3 was signifi-
cantly lower with citrate compared to control. PTX-3 is
associated with cardiovascular morbidity in HD patients
and shown to be induced by the dialysis treatment
[26,27]. Even though not seen in our short term study
citrate dialysis fluid (0.67 mM) used for three months
has been shown to reduce pre-dialysis levels of CRP and
IL-6 [8]. The antioxidative effect of citrate has also been
confirmed in vitro as reduced endothelial apoptosis and
neutrophil activation under hyperglycemic conditions
[17]. Furthermore, the use of citrate as regional anticoagu-
lant during hemodialysis reduced post-dialysis oxidative
stress (ox-LDL) and decreased leukocyte degranulation
and platelet activation during dialysis [28].
Citrate forms complexes with calcium and a potential
concern with citrate dialysis fluids is its effect on sys-
temic ionized calcium. In this study we chose the same
calcium concentration (1.5 mM) in both test and control
fluid to be able to evaluate the effect of citrate on cal-
cium balance. Under these circumstances citrate caused
a small reduction in post-dialysis ionized calcium with a
concomitant increase in post-dialysis PTH compared tocontrol. However all changes were within normal ranges
and no episodes of hypocalcaemia were reported. In
addition, pre-dialysis levels of both PTH and calcium
were similar between products. Since part of the citrate-
calcium complexes formed in the blood are removed
during dialysis citrate dialysis fluids will create a net loss
of calcium compared to traditional fluids with the same
calcium concentration. However, the actual loss is not as
big as indicated by plasma levels of ionized calcium
directly after dialysis since calcium will be released from
the complexes when citrate is metabolized.
Low ionized calcium concentrations may reduce
myocardial contractility and contribute to hypotension
episodes during dialysis. We noticed a small reduction
in MAP during dialysis but there were no indications
of symptomatic hypotension episodes. The reduction
in MAP was evident one hour after treatment start
which may reflect an initial lowering in plasma ionized
calcium. Similar results were seen in a randomized
controlled cross-over study where an increase in calcium
(1.5 vs. 1.25 mM) in the citrate dialysis fluid (0.8 mM)
increased systolic blood pressure and stroke volume
while blood peripheral resistance was reduced [29].
However, work by the same group showed that a citrate
dialysis fluid (0.8 mM) decreased blood peripheral re-
sistance independent of calcium levels, indicating an-
other mechanism besides calcium signaling [25]. Today
the risk of high calcium levels and its role in adynamic
bone disease (ADB) and arterial calcification is as debated
as the risk of low calcium levels, and a high calcium load
in combination with suppressed PTH expression has been
associated with arterial stiffness [30,31]. There is also a
link between inflammation and oxidative stress and hyper-
tension [32].
We have experienced a general concern about the cit-
rate load during HDF, especially during post-dilution
fluid replacement. However, mathematically it has been
established that the solute transport across a dialysis
membrane is dependent on clearance and not mode of
treatment. Even though clearance is generally slightly
higher during post-dilution HDF than during HD, the
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crease in flow rates and/or the membrane permeability
during HD [33]. Our study showed in practice that the
apparent citrate load and change in ionized calcium was
independent of whether the patient was treated with
HD or HDF.
In our study we observed signs of reduced treatment-
induced thrombogenicity with citrate dialysis fluid. Sys-
temically we noticed an intra-dialytic increase in APTT
and in the extracorporeal circuit there was significantly
lower clotting score in the arterial air chamber during
HDF. Even though not supported by our study, an in-
crease in clearance that may be explained by less clotting
in the dialyzer has been reported with citrate dialysis
fluid (0.8 mM) [20]. Some publications claim an ability
to reduce the heparin dose with citrate dialysis fluid
(0.8 mM) but in general these studies are not controlled
[21]. Citrate dialysis fluid may be an alternative or comple-
ment in certain high risk patients but in order to make a
general statement or recommendation about heparin
reduction large controlled studies are needed.
Conclusion
To conclude, citrate dialysis fluid was a safe alternative
during this short term study for both HD and on-line
HDF treatments. Citrate dialysis fluid reduced intra-dialytic
changes in acid–base status by improving pre-dialysis
values of both pH and base excess. In addition citrate
dialysis fluid was associated with reduced treatment-
induced inflammation (PTX-3) and thrombogenicity
(APTT). Although our data need to be confirmed in a
larger study population over longer time, this random-
ized controlled study indicates that citrate dialysis fluid
may be a more biocompatible alternative to conven-
tional acetate containing fluids.
CONSORT guidelines
This study is reported following the CONSORT guide-
lines for randomized controlled trials, Additional file 2:
Table S3 [34,35].
Additional files
Additional file 1: Table S1. Adverse events. Table S2. Biocompatibility
parameters.
Additional file 2: Table S3. CONSORT 2010 checklist of information to
include when reporting a randomised trial.
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